Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Pathog Glob Health ; 118(1): 47-64, 2024 02.
Artigo em Inglês | MEDLINE | ID: mdl-37978995

RESUMO

Toxocariasis is a zoonosis that represents a serious threat to public health particularly in tropical and subtropical areas. Currently, albendazole, the most effective drug for treating visceral toxocariasis, shows moderate efficacy against the larvae in tissues and has some adverse effects. Artemether is an antiparasitic drug mainly used in the treatment of malaria and showed effectiveness against numerous helminthic infections. Besides, it possesses potent anti-inflammatory, antiapoptotic, antifibrotic, and neuroprotective properties. Thus, the study's aim was to investigate artemether's effects in comparison with albendazole on the therapeutic outcome of experimental toxocariasis. For this aim, 140 laboratory-bred mice were divided into four main groups: uninfected control, treatment control, albendazole-treated, and artemether-treated groups. The treatment regimens were started at the 15th dpi (early treatment), and at the 35th dpi (late treatment). The effectiveness of treatment was determined by brain larval count, histopathological, immunohistochemical, and biochemical examination. Artemether showed more effectiveness than albendazole in reducing brain larval counts, markers of brain injury including NF-κB, GFAP, and caspase-3, the diameter and number of hepatic granulomas, hepatic oxidative stress, hepatic IL-6, and TG2 mRNA, and pulmonary inflammation and fibrosis. The efficacy of artemether was the same when administered early or late in the infection. Finally, our findings illustrated that artemether might be a promising therapy for T. canis infection and it could be a good substitution for albendazole in toxocariasis treatment.


Assuntos
Anti-Helmínticos , Toxocaríase , Animais , Camundongos , Toxocaríase/tratamento farmacológico , Toxocaríase/parasitologia , Toxocaríase/patologia , Albendazol/uso terapêutico , Anti-Helmínticos/uso terapêutico , Artemeter/uso terapêutico , Fígado/patologia , Encéfalo/parasitologia , Encéfalo/patologia , Pulmão
2.
Parasitol Res ; 122(12): 3213-3231, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37874393

RESUMO

There are currently insufficient anthelmintic medications available for the treatment of toxocariasis. For instance, Albendazole (ABZ) is the preferred medication, but its effectiveness against tissue-dwelling parasites is limited. In addition, Metformin (MTF) is a widely used oral antidiabetic medication that is considered to be safe for treatment. This study aimed to investigate any potential effects of MTF, alone or in combination with ABZ, on mice infections caused by Toxocara canis (T. canis). The efficacy of the treatment was assessed in the acute and chronic phases of the infection by larval recovery and histopathological, immunohistochemical, and biochemical studies. The results showed that combined therapy significantly reduced larval counts in the liver, brain, and muscles and ameliorated hepatic and brain pathology. It reduced oxidative stress and TGF-ß mRNA expression and increased FGF21 levels in the liver. It decreased TNF-α levels and MMP-9 expression in the brain. In addition, it increased serum levels of IL-12 and IFN-γ and decreased serum levels of IL-4 and IL-10. In the acute and chronic phases of the infection, the combined treatment was more effective than ABZ alone. In conclusion, this study highlights the potential role of MTF as an adjuvant in the treatment of experimental T. canis infection when administered with ABZ.


Assuntos
Metformina , Toxocara canis , Toxocaríase , Camundongos , Animais , Toxocaríase/tratamento farmacológico , Toxocaríase/parasitologia , Metformina/farmacologia , Metformina/uso terapêutico , Albendazol/farmacologia , Albendazol/uso terapêutico , Encéfalo/patologia , Fígado/patologia
3.
Parasitol Res ; 122(12): 2807-2818, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37737322

RESUMO

Trichinellosis is a cosmopolitan zoonosis that is caused mainly by Trichinella spiralis infection. The human disease ranges from mild to severe and fatality may occur. The treatment of trichinellosis still presents a challenge for physicians. Anti-inflammatory drugs are usually added to antiparasitic agents to alleviate untoward immuno-inflammatory responses and possible tissue damage but they are not without adverse effects. Thus, there is a need for the discovery of safe and effective compounds with anti-inflammatory properties. This study aimed to evaluate the activity of ß-glucan during enteral and muscular phases of experimental T. spiralis infection as well as its therapeutic potential as an adjuvant to albendazole in treating trichinellosis. For this aim, mice were infected with T. spiralis and divided into the following groups: early and late ß-glucan treatment, albendazole treatment, and combined treatment groups. Infected mice were subjected to assessment of parasite burden, immunological markers, and histopathological changes in the small intestines and muscles. Immunohistochemical evaluation of NF-κB expression in small intestinal and muscle tissues was carried out in order to investigate the mechanism of action of ß-glucan. Interestingly, ß-glucan potentiated the efficacy of albendazole as noted by the significant reduction of counts of muscle larvae. The inflammatory responses in the small intestine and skeletal muscles were mitigated with some characteristic qualitative changes. ß-glucan also increased the expression of NF-κB in tissues which may account for some of its effects. In conclusion, ß-glucan showed a multifaceted beneficial impact on the therapeutic outcome of Trichinella infection and can be regarded as a promising adjuvant in the treatment of trichinellosis.


Assuntos
Trichinella spiralis , Triquinelose , beta-Glucanas , Camundongos , Humanos , Animais , Triquinelose/tratamento farmacológico , Triquinelose/parasitologia , Albendazol/uso terapêutico , Albendazol/farmacologia , beta-Glucanas/farmacologia , beta-Glucanas/uso terapêutico , NF-kappa B , Músculo Esquelético/parasitologia , Resultado do Tratamento , Anti-Inflamatórios , Larva
4.
Parasitol Res ; 120(7): 2641-2658, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-33945012

RESUMO

Ivermectin (IVM) is one of the competitive treatments used for trichinellosis. However, several studies linked its efficacy with early diagnosis and administration to tackle the intestinal phase with limited activity being recorded against encysted larvae. The aim of this study was to employ niosomes for enhancing effectiveness of oral IVM against different stages of Trichinella spiralis (T. spiralis) infection with reference to nano-crystalline IVM. Mice were randomized into four groups: group Ι, 15 uninfected controls; group ΙΙ, 30 infected untreated controls; group ΙΙΙ, 30 infected nano-crystalline IVM treated, and group ΙV, 30 infected niosomal IVM treated. All groups were equally subdivided into 3 subgroups; (a) treated on the 1st day post infection (dpi), (b) treated on the 10th dpi, and (c) treated on the 30th dpi. Assessment was done by counting adult worms and larvae plus histopathological examination of jejunum and diaphragm. Biochemical assessment of oxidant/antioxidant status, angiogenic, and inflammatory biomarkers in intestinal and muscle tissues was also performed. Both niosomes and nano-crystals resulted in significant reduction in adult and larval counts compared to the infected untreated control with superior activity of niosomal IVM. The superiority of niosomes was expressed further by reduction of inflammation in both jejunal and muscle homogenates. Biochemical parameters showed highly significant differences in all treated mice compared to infected untreated control at different stages with highly significant effect of niosomal IVM. In conclusion, niosomal IVM efficacy exceeded the nano-crystalline IVM in treatment of different phases of trichinellosis.


Assuntos
Antiparasitários/administração & dosagem , Ivermectina/administração & dosagem , Trichinella spiralis/efeitos dos fármacos , Triquinelose/tratamento farmacológico , Animais , Antiparasitários/farmacocinética , Antiparasitários/uso terapêutico , Cromatografia Líquida de Alta Pressão , Diafragma , Inflamação/patologia , Ivermectina/farmacologia , Ivermectina/uso terapêutico , Jejuno/patologia , Larva/efeitos dos fármacos , Lipossomos , Masculino , Camundongos , Nanopartículas , Distribuição Aleatória , Trichinella spiralis/fisiologia , Triquinelose/diagnóstico , Zoonoses
5.
Parasitol Res ; 118(12): 3399-3408, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31655904

RESUMO

Schistosomiasis is a neglected chronic parasitic disease with a significant lasting morbidity. Currently, praziquantel (PZQ) is the most efficient drug for schistosomiasis worldwide. However, the possibility of the occurrence of resistance to PZQ is increasing. Therefore, there is a vital need to find new antischistosomal drugs or to increase the efficacy of the existing ones. Omeprazole is a proton pump inhibitor which is reported to have antiparasitic properties. Thus, the aim of this study was to assess the potential therapeutic effects of omeprazole in experimental Schistosoma mansoni infection either alone or in combination with PZQ. For this aim, 80 laboratory bred mice were divided into 3 groups; uninfected control, infected untreated control, and infected and treated at tenth week P.I. The last group was divided into three subgroups that received either PZQ alone, omeprazole alone, or both drugs. The effectiveness of treatment was assessed by adult worm counts, liver egg count, scanning electron microscopy of adult worms, histopathological, and immunohistochemical (GFAP) examination. There was significant reduction of adult worm counts, liver egg counts, size, diameter of hepatic granulomas, hepatic fibrosis, and GFAP expression in the group that received combined treatment as compared to PZQ group. Moreover, the tegumental changes were more evident in the group that received combined treatment. In conclusion, the administration of omeprazole with PZQ improved the efficacy of PZQ in the treatment of Schistosomiasis mansoni.


Assuntos
Omeprazol/uso terapêutico , Praziquantel/uso terapêutico , Inibidores da Bomba de Prótons/uso terapêutico , Schistosoma mansoni/efeitos dos fármacos , Esquistossomose mansoni/tratamento farmacológico , Esquistossomicidas/uso terapêutico , Animais , Quimioterapia Combinada , Granuloma/parasitologia , Cirrose Hepática/parasitologia , Masculino , Camundongos , Contagem de Ovos de Parasitas , Carga Parasitária , Esquistossomose mansoni/parasitologia
6.
Liver Int ; 34(7): 1033-9, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24575939

RESUMO

BACKGROUND & AIMS: HCV is a major cause of chronic liver disease in Egypt. The aim was to study the prevalence of photosensitivity among asymptomatic HCV-infected patients and its possible relation to porphyrins levels and whether it can be considered an alarm for early diagnosis of the disease, which is the most important goal in the management. METHODS: This study included 100 accidentally discovered HCV positive cases and 100 HCV negative healthy controls. All patients and controls were subjected to: Detailed history and clinical examination, dermatological examination including evaluation of reaction to solar exposure, measurement of serum AST, ALT, albumin, bilirubin, serum and urinary porphyrins levels. RESULTS: The prevalence of photosensitivity among HCV-positive cases (33%) was significantly higher compared to 10% in the control group. Serum porphyrins were positive in 46 cases (46%), twenty-three cases (23%) had positive urinary porphyrins, while only four controls (4%) showed positive serum porphyrins and one (1%) showed positive urinary porphyrins, the difference was statistically significant. Cases with photosensitivity showed significantly higher prevalence of serum and urinary porphyrins existence as well as serum porphyrins levels. Levels of viraemia showed statistically significant relation to levels of porphyrins. CONCLUSION: Asymptomatic chronic HCV infection cases showed significantly high prevalence of photosensitivity, which is related to the associated disturbance of porphyrins metabolism. Photosensitivity can thus be considered an early marker of HCV infection. Patients discovered to have recently acquired photosensitivity should be screened for HCV infection especially in endemic areas like Egypt.


Assuntos
Hepatite C Crônica/complicações , Hepatite C Crônica/diagnóstico , Transtornos de Fotossensibilidade/epidemiologia , Transtornos de Fotossensibilidade/etiologia , Porfirinas/sangue , Porfirinas/urina , Adulto , Alanina Transaminase/sangue , Aspartato Aminotransferases/sangue , Bilirrubina/sangue , Biomarcadores/sangue , Biomarcadores/urina , Egito/epidemiologia , Hepatite C Crônica/epidemiologia , Humanos , Pessoa de Meia-Idade , Transtornos de Fotossensibilidade/sangue , Transtornos de Fotossensibilidade/urina , Prevalência , Albumina Sérica/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...